Research Highlight |
Featured
-
-
Research Highlight |
Apixaban therapy is effective and safe for cancer-associated VTE
Apixaban therapy is as effective as low-molecular-weight heparin therapy for the prevention of recurrence of venous thromboembolism in patients with cancer, with no increase in major bleeding events, according to findings from the Caravaggio trial.
- Irene Fernández-Ruiz
-
Review Article |
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
The cardiotoxicity spectrum of cancer therapies has broadened and is gaining increasing importance with an ever-growing repertoire of therapeutics. This Review provides an updated overview of cardiotoxicity and arrhythmias associated with cancer therapies, summarizing the latest developments at the juncture of cardiology, oncology and haematology and the emerging field of cardio-oncology.
- Joerg Herrmann
-
Review Article |
Vascular toxic effects of cancer therapies
This Review outlines the mechanisms of cancer therapy-related vascular toxicity and provides recommendations for screening, treatment and prevention in the context of available evidence and society guidelines. The Review focuses on the main types of arterial toxicity, acute vasospasm, acute thrombosis and accelerated atherosclerosis, and provides an update on cancer therapy-related venous thromboembolism and pulmonary hypertension.
- Joerg Herrmann
-
-
News & Views |
Cardiovascular disease and breast cancer
Advances in breast cancer therapy mean that more women are surviving cancer but are at increased risk of cardiovascular disease (CVD). In a statement released by the AHA, Mehta and colleagues summarize the intersection between breast cancer and CVD, and highlight the importance of vigilance in preventive measures.
- Melissa Moey
- & Javid Moslehi
-
Review Article |
Pathology, imaging, and treatment of cardiac tumours
Cardiac tumours include a wide array of both neoplastic and non-neoplastic entities. Cardiac tumours are often found incidentally during imaging by ultrasonography, CT, or MRI. In this Review, Maleszewiski and colleagues discuss the clinical presentation, imaging characteristics, pathological characteristics, and treatment of these lesions.
- Joseph J. Maleszewski
- , Nandan S. Anavekar
- & Kyle W. Klarich
-
MI drives progression of breast cancer by promoting a protumoural immune landscape